H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant / National Cancer Institute - LARVOL DELTA

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: National Cancer Institute (NCI) | Phase classification: P2 ➔ P1/2

Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1